ES2156457T3 - Modafinilo con una granulometria definida. - Google Patents

Modafinilo con una granulometria definida.

Info

Publication number
ES2156457T3
ES2156457T3 ES99202603T ES99202603T ES2156457T3 ES 2156457 T3 ES2156457 T3 ES 2156457T3 ES 99202603 T ES99202603 T ES 99202603T ES 99202603 T ES99202603 T ES 99202603T ES 2156457 T3 ES2156457 T3 ES 2156457T3
Authority
ES
Spain
Prior art keywords
modafinilo
modafinil
defined granulometry
granulometry
potency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99202603T
Other languages
English (en)
Inventor
Peter E Grebow
David Stong
Vincent Corvari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23240954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2156457(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon LLC filed Critical Cephalon LLC
Application granted granted Critical
Publication of ES2156457T3 publication Critical patent/ES2156457T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Paints Or Removers (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Slot Machines And Peripheral Devices (AREA)
  • Packaging For Recording Disks (AREA)
  • Laminated Bodies (AREA)

Abstract

EL TAMAÑO DE LA PARTICULA DEL MODAFINIL PUEDE TENER UN EFECTO SIGNIFICATIVO SOBRE LA POTENCIAL Y EL PERFIL DE SEGURIDAD DEL MEDICAMENTO. LA INVENCION DESCRIBE LA UTILIZACION DE CIERTAS COMPOSICIONES FARMACOLOGICAS DE MODAFINIL PARA SU UTILIZACION EN LA ALTERACION DEL ESTADO DE SOMNOLENCIA DE UN MAMIFERO.
ES99202603T 1994-10-06 1995-10-04 Modafinilo con una granulometria definida. Expired - Lifetime ES2156457T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/319,124 US5618845A (en) 1994-10-06 1994-10-06 Acetamide derivative having defined particle size

Publications (1)

Publication Number Publication Date
ES2156457T3 true ES2156457T3 (es) 2001-06-16

Family

ID=23240954

Family Applications (3)

Application Number Title Priority Date Filing Date
ES95937389T Expired - Lifetime ES2142499T3 (es) 1994-10-06 1995-10-04 Modafinil con una granulometria definida.
ES00125091T Expired - Lifetime ES2308960T3 (es) 1994-10-06 1995-10-04 Particulas de mondafinilo que tienen una granulometria definida.
ES99202603T Expired - Lifetime ES2156457T3 (es) 1994-10-06 1995-10-04 Modafinilo con una granulometria definida.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES95937389T Expired - Lifetime ES2142499T3 (es) 1994-10-06 1995-10-04 Modafinil con una granulometria definida.
ES00125091T Expired - Lifetime ES2308960T3 (es) 1994-10-06 1995-10-04 Particulas de mondafinilo que tienen una granulometria definida.

Country Status (34)

Country Link
US (2) US5618845A (es)
EP (3) EP0731698B1 (es)
JP (1) JP2915146B2 (es)
KR (1) KR100249360B1 (es)
AT (3) ATE400260T1 (es)
AU (1) AU703087B2 (es)
BG (1) BG62952B1 (es)
BR (1) BR9509257A (es)
CA (2) CA2201967C (es)
CZ (1) CZ291700B6 (es)
DE (3) DE69520161T2 (es)
DK (3) DK1088549T3 (es)
EE (1) EE9700082A (es)
ES (3) ES2142499T3 (es)
FI (1) FI121454B (es)
GB (1) GB2293103B (es)
GR (2) GR3033152T3 (es)
HK (3) HK1003561A1 (es)
HU (1) HU226411B1 (es)
IS (1) IS1987B (es)
LT (1) LT4303B (es)
LV (1) LV11852B (es)
MD (1) MD970143A (es)
MX (1) MX9602176A (es)
NO (1) NO318818B1 (es)
NZ (1) NZ295869A (es)
PL (1) PL181523B1 (es)
PT (3) PT966962E (es)
RO (1) RO118928B1 (es)
RU (1) RU2287987C2 (es)
SI (1) SI9520106B (es)
SK (1) SK283632B6 (es)
UA (1) UA42023C2 (es)
WO (1) WO1996011001A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
UA71629C2 (en) * 1999-08-03 2004-12-15 Lilli Icos Llc Composition containing free drug particulate form of ?-carboline (variants), method for its manufacture (variants), and method for treating sexual dysfunction
US6346548B1 (en) * 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
US6455588B1 (en) 1999-08-20 2002-09-24 Cephalon, Inc. Compositions including modafinil for treatment of eating disorders and for appetite stimulation
FR2804322B1 (fr) * 2000-01-31 2002-04-19 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament destine a corriger les troubles de la vigilance associes aux myopathies
US20010034373A1 (en) * 2000-02-09 2001-10-25 Matthew Miller Low dose modafinil for enhancement of cognitive function
US6492396B2 (en) 2000-05-16 2002-12-10 Cephalon, Inc. Substituted thioacetamides
EP1309547B1 (en) * 2000-07-27 2007-01-17 Teva Pharmaceutical Industries Ltd. Crystalline and pure modafinil, and process of preparing the same
WO2002030414A1 (en) * 2000-10-11 2002-04-18 Cephalon, Inc. Compositions comprising modafinil compounds
US6919378B2 (en) * 2000-10-11 2005-07-19 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
PL215226B1 (pl) * 2000-10-11 2013-11-29 Cephalon Kompozycja farmaceutyczna zawierajaca zwiazek modafinilu, sposób jej wytwarzania oraz jej zastosowanie
US6489363B2 (en) * 2000-10-11 2002-12-03 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US7704975B2 (en) * 2000-12-19 2010-04-27 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
US7141555B2 (en) 2000-12-19 2006-11-28 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
US7297346B2 (en) * 2001-05-25 2007-11-20 Cephalon Inc. Pharmaceutical formulations of modafinil
US20080058424A1 (en) * 2002-05-23 2008-03-06 Cephalon, Inc. Novel pharmaceutical formulations of modafinil
US7576133B2 (en) 2002-03-11 2009-08-18 Carl Henry Lawyer Methods and compositions for nasal administration of modafinil
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
MY137846A (en) 2002-07-08 2009-03-31 Ranbaxy Lab Ltd Processes for the preparation of oral dosage formulations of modafinil
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
AU2003247001A1 (en) * 2002-07-25 2004-02-16 Ranbaxy Laboratories Limited Processes for the preparation of oral dosage formulations of modafinil
US6992219B2 (en) * 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
US20040116532A1 (en) 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
IL153098A0 (en) * 2002-11-26 2003-06-24 Chemagis Ltd Pharmaceutical compositions containing modafinil
CA2420180A1 (en) * 2003-02-28 2004-08-28 Bernard Charles Sherman Tablets comprising modafinil
US20070066996A1 (en) * 2003-03-17 2007-03-22 Katzman Daniel E Modafinil-based neurorehabilitation of impaired neurological function associated with brian injury
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
ES2330321T3 (es) * 2003-05-16 2009-12-09 Cephalon France Procedimiento de sintesis de modafinilo.
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
US20050137264A1 (en) * 2003-12-22 2005-06-23 Patel Ashish A. Modafinil compositions
EP2292213A1 (en) 2004-02-06 2011-03-09 Cephalon, Inc. Compositions comprising a polymorphic form of armodafinil
US20060024370A1 (en) * 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
GT200600008A (es) * 2005-01-18 2006-08-09 Formulacion de compresion directa y proceso
CA2614777C (en) * 2005-07-21 2012-04-17 Neurohealing Pharmaceuticals, Inc. Rapid onset and short term modafinil compositions and methods of use thereof
EP1951197A4 (en) * 2005-11-10 2011-12-21 Alphapharm Pty Ltd METHOD OF CHECKING THE PARTICLE SIZE
EP2043623A4 (en) * 2006-07-12 2013-03-20 Elan Pharma Int Ltd NANOPARTICLE FORMULATIONS OF MODAFINIL
US7884135B2 (en) * 2006-08-14 2011-02-08 Neurohealing Pharmaceuticals, Inc. Modafinil-based treatment for premature ejaculation
US20080181966A1 (en) * 2006-10-18 2008-07-31 Cephalon, Inc. Modafinil pharmaceutical compositions
EP2476418A1 (en) 2006-12-21 2012-07-18 Alphapharm Pty Ltd. Pharmaceutical compound and composition for use in treating type II diabetes comprising rosiglitazone in a specific particle size
US8173169B2 (en) * 2007-07-11 2012-05-08 Hikma Pharmaceuticals Formulation and process for the preparation of modafinil
US20090325999A1 (en) * 2008-06-27 2009-12-31 Jie Du Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions
US20110206770A1 (en) * 2008-07-25 2011-08-25 Alphapharm Pty. Ltd. Atovaquone with a particle size diameter range (d90) of greater than 3 microns to about 10 microns
US20100036164A1 (en) * 2008-08-06 2010-02-11 Srinivas Areveli Preparation of armodafinil form i
EP2238973A1 (en) 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
FR2987266B1 (fr) * 2012-02-28 2014-12-19 Debregeas Et Associes Pharma Procede d'obtention d'une composition pharmaceutique a base de modafinil, composition pharmaceutique ainsi obtenue et son application
FR2987267B1 (fr) * 2012-02-28 2015-01-16 Debregeas Et Associes Pharma Application du modafinil dans le traitement de substitution des cacainomanes
FR2987265B1 (fr) * 2012-02-28 2014-02-28 Debregeas Et Associes Pharma Composition pharmaceutique sous forme de sirop a base de modafinil, son procede de fabrication et son application
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002718A (en) * 1974-10-16 1977-01-11 Arnar-Stone Laboratories, Inc. Gelatin-encapsulated digoxin solutions and method of preparing the same
FR2408345A1 (fr) * 1976-11-30 1979-06-08 Besins Jean Louis Nouvelle composition a action anti-conceptionnelle
US4122157A (en) * 1977-03-04 1978-10-24 Richardson-Merrell Inc. Nitrofurantoin sustained release tablet
GB1584462A (en) * 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
IT1130924B (it) * 1980-03-06 1986-06-18 Secifarma Spa Procedimento per la preparazione di spironolattone micronizzato
US4600614A (en) * 1983-09-12 1986-07-15 The Dow Chemical Company High-frequency heatable plastics
US4713246A (en) * 1984-03-19 1987-12-15 Bristol-Myers Company Etoposide oral dosage form
IT1187751B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute
FR2593809B1 (fr) * 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
DE3720493A1 (de) * 1987-06-20 1989-01-26 Nattermann A & Cie Arzneizubereitungen mit mikronisierten ebselen-kristallen
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
FR2663225B1 (fr) * 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
FR2684875B1 (fr) * 1991-12-13 1995-05-24 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique.
FR2697162B1 (fr) * 1992-10-23 1995-01-13 Lafon Labor Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux.
FR2702968B1 (fr) * 1993-03-23 1995-06-23 Lafon Labor Procédé de préparation de particules renfermant un ingrédient actif par extrusion et lyophilisation .
JP3795519B2 (ja) 1993-04-05 2006-07-12 エスディーエス プロプライアタリー リミテッド 衝撃式穿孔の改良
FR2706767B1 (es) * 1993-06-22 1995-09-08 Lafon Labor
FR2708201B1 (fr) * 1993-06-30 1995-10-20 Lafon Labor Utilisation de dérivés d'acétamide pour la fabrication de médicaments.
US5493146A (en) 1994-07-14 1996-02-20 Vlsi Technology, Inc. Anti-fuse structure for reducing contamination of the anti-fuse material

Also Published As

Publication number Publication date
HU226411B1 (en) 2008-11-28
SI9520106B (sl) 2003-12-31
ATE199216T1 (de) 2001-03-15
SK44597A3 (en) 1997-09-10
JPH09511754A (ja) 1997-11-25
GB9524328D0 (en) 1996-01-31
DK1088549T3 (da) 2008-11-17
HUT77778A (hu) 1998-08-28
ES2308960T3 (es) 2008-12-16
IS4451A (is) 1997-03-24
GB2293103B (en) 1997-05-07
EP0966962A1 (en) 1999-12-29
PL319480A1 (en) 1997-08-04
GB2293103A (en) 1996-03-20
EP1088549A1 (en) 2001-04-04
DK0731698T3 (da) 2000-05-08
DE69520161T2 (de) 2001-08-02
PL181523B1 (en) 2001-08-31
LV11852A (lv) 1997-10-20
DE69520161D1 (de) 2001-03-29
PT966962E (pt) 2001-06-29
LV11852B (en) 1998-03-20
US5618845A (en) 1997-04-08
AU703087B2 (en) 1999-03-18
FI971417A (fi) 1997-04-04
EP1088549B1 (en) 2008-07-09
MX9602176A (es) 1997-05-31
DE69514497T2 (de) 2000-08-10
RU2287987C2 (ru) 2006-11-27
HK1003561A1 (en) 1998-10-30
CA2201967C (en) 2002-12-10
GR3033152T3 (en) 2000-08-31
ATE188607T1 (de) 2000-01-15
ES2142499T3 (es) 2000-04-16
BG62952B1 (bg) 2000-12-29
HK1024625A1 (en) 2000-10-20
CZ291700B6 (cs) 2003-05-14
BG101389A (en) 1997-12-30
NZ295869A (en) 1998-02-26
LT4303B (lt) 1998-03-25
DK0966962T3 (da) 2001-03-19
RO118928B1 (ro) 2004-01-30
GR3035451T3 (en) 2001-05-31
LT97060A (en) 1997-10-27
KR100249360B1 (ko) 2000-04-01
CA2382275A1 (en) 1996-04-18
NO971541D0 (no) 1997-04-04
CZ103297A3 (en) 1997-09-17
JP2915146B2 (ja) 1999-07-05
PT731698E (pt) 2000-05-31
HK1034676A1 (en) 2001-11-02
CA2201967A1 (en) 1996-04-18
EP0731698B1 (en) 2000-01-12
SI9520106A (sl) 1998-02-28
SK283632B6 (sk) 2003-11-04
WO1996011001A1 (en) 1996-04-18
NO971541L (no) 1997-06-04
BR9509257A (pt) 1998-07-07
UA42023C2 (uk) 2001-10-15
ATE400260T1 (de) 2008-07-15
AU3951495A (en) 1996-05-02
CA2382275C (en) 2003-12-16
IS1987B (is) 2005-02-15
DE69514497D1 (de) 2000-02-17
NO318818B1 (no) 2005-05-09
EE9700082A (et) 1997-10-15
DE69535786D1 (de) 2008-08-21
EP0731698A1 (en) 1996-09-18
FI121454B (fi) 2010-11-30
FI971417A0 (fi) 1997-04-04
MD970143A (ro) 1998-12-31
EP0966962B1 (en) 2001-02-21
USRE37516E1 (en) 2002-01-15
PT1088549E (pt) 2008-09-23

Similar Documents

Publication Publication Date Title
ES2142499T3 (es) Modafinil con una granulometria definida.
CY1107714T1 (el) Φαρμακευτικες συνθεσεις μοδαφινιλιου
BR9407306A (pt) Composição farmacêutica para a administação oral e processo para preparar a mesma
NO920204L (no) Farmasoeytisk preparat og fremgangsmaate for dets fremstilling
ZA951418B (en) 2-(4-methoxyphenoxy)-3-pyridineamine its pharmaceutical compositions and therapeutic use
MY138052A (en) Modafinil pharmaceutical compositions
NO920063D0 (no) Farmasoeytisk preparat og dets anvendelse
ZA906792B (en) Pharmaceutical compositions and a device for administering the same
KR940026144U (ko) 약용 동물용 믹서기
ZA906208B (en) Paracetamol solutions and pharmaceutical formulations

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 966962

Country of ref document: ES